Tapping evolution to improve biotech products October 06, 2016, 10:20

Other common protein-based drugs include monoclonal antibodies, insulin, human growth hormone and white blood cell stimulating factors given to cancer patients.

The authors say that ASR-based engineering could be applied to other recombinant proteins produced outside the human body, as well as gene therapy.

It has been possible to produce human factor VIII in recombinant form since the early 1990s. However, current factor VIII products still have problems: they don’t last long in the blood, they frequently stimulate immune responses in the recipient, and they are difficult and costly to manufacture.

Experimental hematologist and gene therapist Chris Doering, PhD and his colleagues already had some success in addressing these challenges by filling in some of the sequence of human factor VIII with the same protein from pigs.

«We hypothesized that human factor VIII has evolved to be short lived in the blood to reduce the risk of thrombosis," Doering says. «And we reasoned that by going even farther back in evolutionary history, it should be possible to find more stable, potent relatives.»

Doering is associate professor of pediatrics at Emory University School of Medicine and Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta. The first author of the paper is former Molecular and Systems Pharmacology graduate student Philip Zakas, PhD.

Doering’s lab teamed up with, Trent Spencer, PhD, director of cell and gene therapy for the Aflac Cancer and Blood Disorders Center, and Eric Gaucher, PhD, associate professor of biological sciences at Georgia Tech, who specializes in ASR.

ASR involves reaping the recent harvest of genome sequences from animals as varied as mice, cows, goats, whales, dogs, cats, horses, bats and elephants. Using this information, scientists reconstruct a plausible ancestral sequence for a protein in early mammals. They then tweak the human protein, one amino acid building block at a time, toward the ancestral sequence to see what kinds of effects the changes could have.

The research team showed that amino acid changes toward ancestral sequences could make human factor VIII more stable and less likely to be inhibited by recipient antibodies.

‘This exemplifies how understanding the evolutionary history of a protein can help engineer better versions of the protein for therapeutic use," Gaucher says.

«ASR is a widely accessible strategy that utilizes both known and unknown natural protein diversity to rapidly probe a protein design space that has already been
refined by natural selection for beneficial properties," the authors conclude.

The research was supported by the National Heart Lung and Blood Institute (U54HL112309), a research partnership between Children’s Healthcare of Atlanta and Georgia Tech, and Bayer. Several authors are inventors on a patent application describing ancestral factor VIII technology filed by Emory University, Children’s Healthcare of Atlanta and Georgia Tech. Doering and co-author H. Trent Spencer are co-founders and stockholders of Expression Therapeutics, which owns the intellectual property for the part-porcine factor VIII. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies.

Source: http://news.emory.edu/stories/2016/09/doering_asr_nbt/index.html